Form 4: Bio-Rad Laboratories Director Acquires Shares Through Vesting of Restricted Stock Units

Gregory K. Hinckley, a director at Bio-Rad Laboratories, acquired 308 shares of Class A common stock through the vesting of restricted stock units on April 22, 2025.

Summary

• On April 22, 2025, Gregory K. Hinckley, a director of Bio-Rad Laboratories, acquired 308 shares of Class A common stock.
• This acquisition resulted from the vesting of restricted stock units.
• Hinckley also received 407 restricted stock units that will vest 100% on the earlier of the first anniversary of the grant date or the date of the company's next annual meeting of stockholders.
• Additionally, 308 restricted stock units were granted on September 6, 2024, vesting at 100% on the earlier of the first anniversary of the grant date or the date of the Company's next annual stockholder meeting following the grant date.
• Following the transaction, Hinckley directly owns 308 shares of Bio-Rad A Common Stock and 407 Restricted Stock Units.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction related to executive compensation, which is neither particularly positive nor negative. It indicates standard corporate governance practices.

Positives

• The vesting of restricted stock units indicates a continued alignment of the director's interests with those of the shareholders.

Future Outlook

The restricted stock units will vest 100% on the earlier of the first anniversary of the grant date or the date of the company's next annual meeting of stockholders.

Industry Context

This is a routine disclosure related to executive compensation and equity ownership, common in publicly traded companies.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns the director's interests with the company's performance.

Key Dates

Keywords

Bio-Rad Laboratories, Director, Gregory K. Hinckley, Class A Common Stock, Restricted Stock Units, Vesting, Acquisition, Form 4, SEC